Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Steve PakolaChief Medical Officer | RegenxbioRGNX | Open-market sale10b5-1 plan | 05/11 | 05/13 | 15,309 sh | $11.02 | $168,705.18 | −6.2% |
Steve PakolaChief Medical Officer | RegenxbioRGNX | Open-market sale10b5-1 plan | 03/10 | 03/12 | 5,124 sh | $10.35 | $53,033.4 | −2.0% |
RegenxbioRGNX | Open-market sale10b5-1 plan | 25/10/09 | 25/10/10 | 20,811 sh | $12.62 | $262,634.82 | −8.8% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 25/09/29 | 25/10/01 | 7,624 sh | $10.03 | $76,468.72 | −3.1% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 25/09/10 | 25/09/12 | 7,734 sh | $10.02 | $77,494.68 | −3.1% | |
Kenneth T. MillsDirector | RegenxbioRGNX | Open-market sale10b5-1 plan | 25/05/12 | 25/05/14 | 20,602 sh | $7.91 | $162,961.82 | −4.2% |
Argeris N. KarabelasDirector | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/10/01 | 24/10/02 | 10,000 sh | $10.11 | $101,100 | −47.0% |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/09/03 | 24/09/04 | 10,000 sh2 trades | $11.56avg. | $115,588 | −47.0% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/08/01 | 24/08/05 | 10,100 sh3 trades | $13.51avg. | $136,456 | −47.2% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/08/01 | 24/08/05 | 100 sh | $15.00 | $1,500 | −0.1% | |
Argeris N. KarabelasDirector | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/07/29 | 24/07/30 | 11,000 sh | $15.05 | $165,550 | −49.4% |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/07/29 | 24/07/30 | 9,648 sh | $15.04 | $145,105.92 | −5.4% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/07/24–24/07/25 | 24/07/26 | 27,590 sh2 trades | $13.88avg. | $382,956.62 | −6.3% | |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/07/16–24/07/17 | 24/07/18 | 2,410 sh2 trades | $13.77avg. | $33,183.7 | −0.6% | |
Argeris N. KarabelasDirector | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/07/01 | 24/07/03 | 10,000 sh | $11.27 | $112,700 | −47.0% |
Kenneth T. MillsPresident and CEO | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/05/14 | 24/05/16 | 15,000 sh | $15.81 | $237,150 | −3.5% |
Kenneth T. MillsPresident and CEO | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/04/15 | 24/04/17 | 15,000 sh | $18.19 | $272,850 | −3.5% |
Kenneth T. MillsPresident and CEO | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/03/14 | 24/03/18 | 15,000 sh | $21.86 | $327,900 | −3.5% |
Steve PakolaChief Medical Officer | RegenxbioRGNX | Open-market sale10b5-1 plan | 24/03/05 | 24/03/07 | 12,878 sh | $28.36 | $365,220.08 | −10.7% |
RegenxbioRGNX | Open-market sale10b5-1 plan | 24/02/14 | 24/02/16 | 15,000 sh2 trades | $16.75avg. | $251,292.68 | −3.5% |